A dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-small cell lung cancer (NSCLC) of squamous histology

Trial Profile

A dose-finding phase Ib study followed by a randomized, double-blind phase II study of carboplatin and paclitaxel with or without buparlisib in patients with previously untreated metastatic non-small cell lung cancer (NSCLC) of squamous histology

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Buparlisib (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms BASALT-2
  • Sponsors Novartis
  • Most Recent Events

    • 31 Jul 2017 This trial has been completed in UK as per European Clinical Trials Database record.
    • 18 Aug 2016 This trial has been completed in France as per European Clinical Trials Database record.
    • 07 Jun 2016 Results from this trial and other trial (BASALT-3) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top